Corresponding Author: Yong Zhu, Yale School of Public Health, Yale School of Medicine, New Haven, CT 06520, USA.
Cancer Epidemiol Biomarkers Prev. 2013 Mar;22(3):327-36. doi: 10.1158/1055-9965.EPI-12-1131-T. Epub 2013 Jan 18.
miRNAs have been implicated in numerous tumorigenic pathways, and previous studies have associated miR-202 dysregulation with various cancer types, including follicular lymphoma.
The miR-202 targetome was identified by ribonucleoprotein immunoprecipitation-microarray (RIP-Chip), and functional interactions among identified targets were investigated using the Ingenuity Pathway Analysis tool. We also conducted a population-based genetic association study of a polymorphism within the miR-202 stem-loop sequence and risk of non-Hodgkin lymphoma. In vitro gain-of-function experiments were further conducted to elucidate the functional significance of the variant.
A total of 141 potential members of the miR-202 targetome were identified by a transcriptome-wide RIP-Chip assay. Functional interactions among identified targets suggested that miR-202-regulated genes are involved in biologic pathways relevant for hematologic function and cancer. Consistent with this, a genetic association analysis using human blood samples revealed a significant association between a germline mutation (rs12355840) in the miR-202 precursor sequence and follicular lymphoma risk. An in vitro functional assay further showed that the variant allele resulted in diminished miR-202 levels, possibly by altering precursor-processing efficiency.
Taken together, our findings suggest that miR-202 is involved in follicular lymphomagenesis.
These findings implicate miR-202 as a potential tumor suppressor in follicular lymphoma and warrant the investigation of miR-202 as a novel biomarker of follicular lymphoma risk.
miRNAs 参与了许多肿瘤发生途径,先前的研究将 miR-202 失调与各种癌症类型相关联,包括滤泡性淋巴瘤。
通过核糖核蛋白免疫沉淀微阵列(RIP-Chip)鉴定 miR-202 的靶标组,使用 Ingenuity 通路分析工具研究鉴定靶标之间的功能相互作用。我们还进行了 miR-202 茎环序列内多态性与非霍奇金淋巴瘤风险的基于人群的遗传关联研究。进一步进行了体外功能获得实验,以阐明变体的功能意义。
通过全转录组 RIP-Chip 分析鉴定了总共 141 个潜在的 miR-202 靶标组成员。鉴定靶标之间的功能相互作用表明,miR-202 调节的基因参与与血液功能和癌症相关的生物学途径。与此一致,使用人类血液样本的遗传关联分析显示,miR-202 前体序列中的种系突变(rs12355840)与滤泡性淋巴瘤风险之间存在显著关联。体外功能测定进一步表明,变体等位基因导致 miR-202 水平降低,可能通过改变前体处理效率。
总的来说,我们的发现表明 miR-202 参与了滤泡性淋巴瘤的发生。
这些发现表明 miR-202 是滤泡性淋巴瘤中的潜在肿瘤抑制因子,并需要进一步研究 miR-202 作为滤泡性淋巴瘤风险的新型生物标志物。